RT Journal Article
SR Electronic
T1 An Interpretable Machine Learning Tool for In-Home Screening of Agitation Episodes in People Living with Dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.30.24311178
DO 10.1101/2024.07.30.24311178
A1 Bafaloukou, Marirena
A1 Schalkamp, Ann-Kathrin
A1 Fletcher-Lloyd, Nan
A1 Capstick, Alex
A1 Walsh, Chloe
A1 Sandor, Cynthia
A1 Kouchaki, Samaneh
A1 ,
A1 Nilforooshan, Ramin
A1 Barnaghi, Payam
YR 2024
UL http://medrxiv.org/content/early/2024/08/01/2024.07.30.24311178.abstract
AB Background Agitation affects around 30% of people living with dementia (PLwD), increasing carer burden and straining care services. Agitation screening typically relies on subjective clinical scales and direct patient observation, which are resource-intensive and challenging to incorporate into routine care. Clinical applicability of data-driven methods for agitation screening is limited by constraints such as short observational periods, data granularity, and lack of interpretability and generalisability. Current interventions for agitation are primarily medication-based, which may lead to severe side effects and lack personalisation. Understanding how real-world factors affect agitation within home settings offers a promising avenue towards identifying potential personalised non-pharmacological interventions.Methods We used longitudinal data (32,896 person-days from n=63 PLwD) collected using in-home monitoring devices. Employing machine learning techniques, we developed a screening tool to determine the weekly risk of agitation. We incorporated a traffic-light system for risk stratification to aid clinical decision-making and employed the SHapley Additive exPlanations (SHAP) framework to increase interpretability. We designed an interactive tool that enables the exploration of personalised non-pharmacological interventions, such as modifying ambient light and temperature.Results Light Gradient-boosting Machine (LightGBM) achieved the highest performance in identifying agitation with a sensitivity of 71.32±7.38% and specificity of 75.28%. Implementing the traffic-light system for risk stratification increased specificity by 15% and improved all metrics. Significant contributors to agitation included low nocturnal respiratory rate, heightened alertness during sleep, and increased indoor illuminance, as revealed by statistical and feature importance analysis. Using our interactive tool, we identified that adjusting indoor lighting levels and temperature were promising and feasible interventions within our cohort.Conclusions Our interpretable framework for agitation screening, developed using data from a dementia care study, showcases significant clinical value. The accompanying interactive interface allows for the in-silico simulation of non-pharmacological interventions, facilitating the design of personalised interventions that can improve in-home dementia care.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.isrctn.com/ISRCTN71000991 Funding StatementThis study is funded by the UK Dementia Research Institute [award number UK DRI-7002] through UK DRI Ltd, funded by the Medical Research Council (MRC), Alzheimer's Research UK, Alzheimer's Society, and the UKRI Engineering and Physical Sciences Research Council (EPSRC) PROTECT Project (grant number: EP/W031892/1). Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC) and the UKRI Medical Research Council (MRC).The funders were not involved in the study design, data collection, data analysis or writing the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the London-Surrey Borders Research Ethics Committee; TIHM 1.5 REC 19/LO/0102. The study is registered with the National Institute for Health and Care Research (NIHR) in the United Kingdom under the Integrated Research Application System (IRAS) registration number 257561.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUnidentified patient data can become available from the corresponding author upon reasonable request. The trained model is available at: https://huggingface.co/spaces/marirena/AgitationScreening/tree/main.